Board Unveils New Foresight and Signals Products: Revolutionizing Business Planning with AI and Economic Intelligence
19.2.2025 15:00:00 CET | Business Wire | Press release
Board, the leading Enterprise Planning Platform, is transforming the way businesses anticipate and adapt to economic shifts with today’s announcement of Board Foresight and Board Signals. These cutting-edge solutions, developed as a result of Board’s recent acquisition of Prevedere, empower enterprises with real-time economic indicators, predictive analytics, and the expertise of Board’s in-house economists—all backed by exclusive access to over 5 million global datasets.
This release marks a huge step forward in completing Board’s product vision. By harnessing the power of macroeconomic intelligence, the Board Enterprise Planning Platform now enables more comprehensive, collaborative, and continuous planning capabilities than ever before. Board Foresight and Signals give business leaders the ability to look beyond internal historical data, forecast with greater accuracy, scenario plan with more agility, and make strategic decisions with confidence in an increasingly volatile world.
Board Foresight: Continuous planning with external data, AI, and predictive analytics
Board Foresight takes business forecasting to the next level by unlocking the power of external data with expert-curated economic indicators, an advanced correlation engine, and predictive analytics. With real-time updates from millions of external sources, Board Foresight enables enterprises to anticipate market shifts, align business strategies and drive continuous planning.
Key benefits of Board Foresight:
- Expert-Curated Indicators: Get a list of the external factors most likely to impact your industry.
- Powerful Correlation Engine: Connect to your own internal time series data and Foresight will run millions of models to identify your most relevant performance drivers.
- Results Explained by AI: Get a complete understanding of the external factors impacting your business, with clear explanation and interpretation delivered through generative AI.
- Predictive Forecasting to Support Continuous Planning: Forecast with better accuracy and turn continuous planning into a competitive advantage.
Learn more at https://www.board.com/en/product/foresight.
Board Signals: Make smarter strategic decisions with expert-curated external data
Board Signals provides decision-makers with real-time, industry-specific economic indicators to help them navigate market volatility with confidence. Designed for strategic planners, executive officers, and board members, Board Signals delivers clear, actionable intelligence to drive smarter business decisions and is available today.
Key benefits of Board Signals:
- Industry-Specific Economic Intelligence: Get expert-curated indicators tailored to your industry, monitored and updated regularly by Board’s in-house economists.
- Smart Alerts on Market Volatility: Receive real-time alerts on headwinds and tailwinds impacting your business so you can respond in an agile manner to capitalize on opportunities and mitigate risks.
- Indicator Reports and Industry Outlook Score: Visualize economic conditions with intuitive reports and scoring to support strategic decision-making.
Learn more at https://www.board.com/en/product/signals.
An Innovative Breakthrough in Enterprise Planning
David Marmer, SVP of Product at Board, emphasized the significance of these new solutions:
“The introduction of Board Foresight and Board Signals marks a new beginning for enterprise planning. For too long, businesses have relied solely on historical internal data, missing the critical external factors that drive success or failure. With the power of over 5 million datasets, AI-driven analytics, and expert economic intelligence, our customers can now plan continuously for the future with greater confidence and precision. These innovations reflect Board’s commitment to giving our customers the tools they need to stay ahead.”
Visionary Brands are Leading the Way
Leading enterprises are already leveraging Board Signals and Board Foresight to enhance their decision-making. Milwaukee Tool, Whataburger, and Kraft Heinz are among the early adopters benefiting from these solutions, using them to navigate economic volatility, optimize inventory, and drive strategic growth.
“This has been a game-changer for Whataburger,” says Pete Valadez, Senior Director of Financial Planning & Analysis at Whataburger. “By incorporating external data and predictive analytics into our forecasting process, we’ve been able to dramatically improve our accuracy and avoid missed expectations. The real-time alerts and collaborative nature of the solution have empowered our entire team to make data-driven decisions with confidence.”
General Availability
Board Signals and Board Foresight are available now globally.
About Board
The Board Enterprise Planning Platform powers financial and operational planning for more than 2,000 organizations worldwide. Industry leaders trust Board to turn complex data into better decisions with AI, analytics, and tailor-made solutions for enterprise-grade challenges. Global brands including H&M, BASF, Burberry, Toyota, Coca-Cola, KPMG, and HSBC use Board to enhance workflows and strengthen their competitive edge. Founded in 1994, and now with 25 offices worldwide, Board is recognized by leading analysts including Gartner, IDC, and BARC.
For more information, visit www.board.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219004034/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom